Malignant effusions contain lysophosphatidic acid (LPA)-like activity

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 437-442

  Westermann, A M ^a   Havik, E ^a   Postma, F R ^a   Beijnen, J H ^a   Dalesio, O ^a   Moolenaar, W H ^a   Rodenhuis, S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Ascites; Growth factors; Lysolipids; Lysophosphatidic acid; Ovarian cancer

Indexed keywords

CELL SURFACE RECEPTOR; GROWTH FACTOR; LYSOPHOSPHATIDIC ACID; PHOSPHOLIPID; SPHINGOSINE 1 PHOSPHATE;

ANIMAL CELL; ARTICLE; ASCITES; BIOASSAY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; OVARY CANCER; PLEURA FLUID; PRIORITY JOURNAL;

ADENOCARCINOMA; ASCITIC FLUID; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; LYSOPHOSPHOLIPIDS; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0031747415     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008217129273     Document Type: Article

References (20)

1. Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S. Growth factors in human ovarian cancer. Cancer Treat Rev 1997; 23: 113-31.
2. Broxterman HJ, Sprenkels-Schotte C, Engelen Ph et al. Analysis of human ascites effect on clonogenic growth of human tumor cell lines and NRK-49F cells in soft agar. Int J Cell Cloning 1987; 5: 158-69.
3. Uitendaal MP, Hubers HAJM, McVie JG, Pinedo HM. Human tumour clonogenicity in agar is improved by cell-free ascites. Br J Cancer 1983; 48: 55-9.
4. Mills GB, May C, McGill M et al. A putative new growth factor in ascitic fluid from ovarian cancer patients: Identification, characterization, and mechanism of action. Cancer Res 1988; 48: 1066-71.
5. Mills GB, May C, Hill M et al. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990; 86: 851-5.
6. Xu Y, Mills GB. Ovarian Cancer 3. In Sharp F, Mason P, Blackett T, Berek J (eds): Activation of Human Ovarian Cancer Cells: Role of Lipid Factors in Ascitic Fluid. London: Chapman & Hall 1995; 121-35.
7. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-80.
8. Van Corven EJ, Groenink A, Jalink K et al. Lysophosphatidate-induced cell proliferation: Identification and dissection of signalling pathways mediated by G proteins. Cell 1989; 59: 45-54.
9. Jalink K, Hordijk PL, Moolenaar WH. Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator. Biochim Biophys Acta 1994; 1198: 185-96.
10. Imamura F, Horai T, Mukai M et al. Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem Biophys Res Commun 1993; 193: 497-503.
11. Xu Y, Fang X-J, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995; 309: 933-40.
12. Jalink K, Eichholz T, Postma FR et al. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor mediated signaling pathway: Similarity to thrombin action. Cell Growth Diff 1993; 4: 247-55.
13. Postma FR, Jalink K, Hengeveld T, Moolenaar WH. Sphingosine-1-phosphate rapidly induces Rho-dependent neurite retraction: Action through a specific cell surface receptor. EMBO J 1996; 15: 2388-95.
14. Moolenaar WH, Van der Bend RL, Van Corven EJ et al. Lysophosphatidic acid: A novel phospholipid with hormone- and growth factor-like activities. Cold Spring Harb Symp Quant Biol 1992; 17: 163-7.
15. Van Corven EJ, Van Rijswijk A, Jalink K, Van der Bend RL, Van Blitterswijk WJ, Moolenaar WH. Lysophosphatidate-inducxed cell proliferation: Identification and dissection of signalling pathways mediated by G proteins. Cell 1989; 59: 45-54.
16. Moolenaar WH. LPA: A novel lipid mediator with diverse biological action. Trends Cell Biol 1994; 4: 213-9.
17. Stein CA. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53: 2239-48.
18. Van der Bend RL, Brunner J, Jalink K et al. Identification of a putative membrane receptor for the bioactive phospholipid, lysophosphatidic acid. EMBO J 1992; 11: 2495-501.
19. Kikuchi Y, Hirata J, Hisano A et al. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol 1995; 58: 11-5.
20. Van Corven EJ, Van Rijswijk A, Jalink K et al. Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Biochem J 1992; 281: 163-9.